Becton DickinsonBDX +2.44%76 3-Year ROIIC % is 41.41 as of Sep. 2025, which is 1604% above its 10-year median of 2.43. GuruFocus rates BDX with a GF Score™ of 76/100 and a GF Value™ of $191.05 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 801 Medical Devices & Instruments companies, Becton Dickinson ranks better than 81.27% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Becton Dickinson's 3-Year ROIIC % for the quarter that ended in Sep. 2025 was 41.41%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Becton Dickinson's 3-Year ROIIC % or its related term are showing as below:
BDX's 3-Year ROIIC % is ranked better than 81.27% of 801
companies
in the Medical Devices & Instruments industry
Industry Median: 1.12
vs BDX: 41.41
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Becton Dickinson 3-Year ROIIC % Related Terms
Becton Dickinson 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Becton Dickinson's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Becton Dickinson's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Becton Dickinson 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Becton Dickinson's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Becton Dickinson's 3-Year ROIIC % falls into.
Becton Dickinson's 3-Year ROIIC % for the quarter that ended in Sep. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 2663.8106 (Sep. 2025) - 2269.575 (Sep. 2022) )
/
( 47924 (Sep. 2025) - 46972 (Sep. 2022) )
=
394.2356
/
952
=
41.41%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Becton Dickinson (BDX) has a 3-Year ROIIC % of 41.41 as of Sep. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Becton Dickinson and its competitors. This is 1604% above median its historical median of 2.43. According to the industry distribution chart, Becton Dickinson ranks #150 out of 801 companies in the Medical Devices & Instruments industry, placing it in the top 18.7%.
Is Becton Dickinson's 3-Year ROIIC % too high?
Becton Dickinson's current 3-Year ROIIC % of 41.41 is 1604% above median its 10-year median of 2.43. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.12. Becton Dickinson's value of 41.41 is 3597.3% above this industry median. Based on the distribution chart, Becton Dickinson ranks #150 out of 801 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Becton Dickinson has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Becton Dickinson's 3-Year ROIIC % compare to MDLN and RMD?
According to the Medical Devices & Instruments industry distribution chart, Becton Dickinson ranks #150 out of 801 companies for 3-Year ROIIC %. This places Becton Dickinson in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.12. Becton Dickinson's value of 41.41 is 3597.3% above this benchmark. While the company's 10-year median is 2.43 vs. the industry median of 1.12, Becton Dickinson has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.12, based on 801 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Becton Dickinson's current 3-Year ROIIC % of 41.41 is 3597.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Becton Dickinson and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Becton Dickinson's current 3-Year ROIIC % is 41.41, which is 1604% above median its own 10-year median of 2.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Becton Dickinson stock overvalued right now?
Based on GuruFocus' analysis, Becton Dickinson (BDX) is currently considered Modestly Undervalued. The stock's GF Value™ is $191.05, compared to a current price of $151.38 — trading 20.8% below its estimated fair value. The current 3-Year ROIIC % is 41.41, which is 1604% above median its 10-year median of 2.43 and 3597.3% above the Medical Devices & Instruments industry median of 1.12. Becton Dickinson's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Becton Dickinson (BDX), the current 3-Year ROIIC % is 41.41 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Becton Dickinson (BDX) Overvalued in 2026?
Based on GuruFocus' analysis, Becton Dickinson stock appears to be undervalued.
The current stock price of $151.38 is trading 20.8% below its estimated GF Value™ of $191.05.
GuruFocus considers Becton Dickinson to be Modestly Undervalued.
Key valuation signals for BDX:
3-Year ROIIC %: 41.41 (1604% above median its 10-year median of 2.43)
GF Value™: $191.05 vs. price of $151.38 (20.8% below fair value)
Industry Position: 3597.3% above the Medical Devices & Instruments median (#150 of 801)
No single metric tells the full story. See the BDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
76GF Score
Get the complete analysis for BDX
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDX has been successfully added to your 
